PIOGLITAZONE HYDROCHLORIDE AND GLIMEPIRIDE
Clinical safety rating: safe
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and bladder cancer.
Pioglitazone is a thiazolidinedione that acts as an agonist at peroxisome proliferator-activated receptor gamma (PPARγ), increasing insulin sensitivity in peripheral tissues and reducing hepatic gluconeogenesis. Glimepiride is a sulfonylurea that stimulates insulin secretion from pancreatic beta cells by blocking ATP-sensitive potassium channels.
| Metabolism | Pioglitazone is metabolized primarily by CYP2C8 and to a lesser extent CYP3A4; glimepiride is metabolized by CYP2C9 to active metabolites. |
| Excretion | Pioglitazone: 30% renal (as metabolites, <2% unchanged); 70% fecal/biliary. Glimepiride: 60% renal (metabolites), 40% fecal/biliary. |
| Half-life | Pioglitazone: 3–7 hours (parent), 16–24 hours (active metabolites); clinically, once-daily dosing due to metabolite activity. Glimepiride: 5–9 hours (terminal), with prolonged effect in renal impairment. |
| Protein binding | Pioglitazone: >99% bound (albumin). Glimepiride: >99.5% bound (albumin). |
| Volume of Distribution | Pioglitazone: 0.25 L/kg. Glimepiride: 0.17 L/kg. Both indicate limited extravascular distribution. |
| Bioavailability | Oral: Pioglitazone 83% (absolute). Glimepiride 100% (absolute, well absorbed). |
| Onset of Action | Oral: Pioglitazone 2–4 weeks for full glycemic effect; Glimepiride 1–3 hours after a single dose. |
| Duration of Action | Pioglitazone: 24 hours (once-daily dosing). Glimepiride: 24 hours (once-daily), but hypoglycemia risk can extend beyond 24 hours in overdose or renal impairment. |
Oral, 1 tablet containing pioglitazone 15-30 mg and glimepiride 1-4 mg once daily with the first main meal; maximum daily doses: pioglitazone 45 mg, glimepiride 8 mg.
| Dosage form | TABLET |
| Renal impairment | Contraindicated if eGFR <30 mL/min/1.73 m² due to glimepiride; if eGFR 30-60, consider dose reduction of glimepiride to avoid hypoglycemia; no specific adjustment for pioglitazone. |
| Liver impairment | Contraindicated in Child-Pugh class B and C; limited data in class A, use with caution and consider lower starting doses. |
| Pediatric use | Not recommended in pediatric patients (under 18 years) due to lack of safety and efficacy data. |
| Geriatric use | Initiate at lowest combination strength (pioglitazone 15 mg/glimepiride 1 mg) due to increased risk of hypoglycemia and fluid retention; monitor renal function and avoid if eGFR <30. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Strong CYP2C8 inhibitors may increase levels Can cause or exacerbate congestive heart failure and bladder cancer.
| FDA category | Animal |
| Breastfeeding | Not recommended. Pioglitazone: unknown excretion in human milk; glimepiride: may be excreted (M/P ratio not established). Potential for neonatal hypoglycemia and adverse effects. Avoid breastfeeding. |
| Teratogenic Risk | Pregnancy category C. First trimester: Data insufficient; avoid due to potential teratogenicity. Second and third trimesters: Pioglitazone crosses placenta; glimepiride may cause neonatal hypoglycemia, macrosomia, and respiratory distress. Increased risk of congenital anomalies with sulfonylureas reported but not confirmed. Use only if benefit outweighs risk. |
■ FDA Black Box Warning
Thiazolidinediones, including pioglitazone, may cause or exacerbate congestive heart failure. Pioglitazone is not recommended in patients with symptomatic heart failure. Glimepiride, like all sulfonylureas, is associated with an increased risk of cardiovascular mortality when used as monotherapy.
| Common Effects | Headache Sore throat Sinus inflammation Muscle pain |
| Serious Effects |
Known hypersensitivity to pioglitazone, glimepiride, or any sulfonylurea; type 1 diabetes mellitus; diabetic ketoacidosis; severe renal or hepatic impairment; concomitant use with certain CYP2C8 inhibitors or inducers; and use during labor and delivery.
| Precautions | Congestive heart failure, edema, weight gain, hypoglycemia (especially in elderly, debilitated, or renal/hepatic impairment), increased risk of fractures (primarily in female patients), hemolytic anemia in G6PD deficiency, hepatotoxicity, and acute pancreatitis. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood glucose, HbA1c, and renal function. Fetal monitoring: serial ultrasound for growth (macrosomia risk) and amniotic fluid index (polyhydramnios). Neonatal: monitor for hypoglycemia, jaundice, and respiratory distress after delivery. |
| Fertility Effects | No significant adverse effects on fertility reported in animal studies. Pioglitazone may improve ovulation in polycystic ovary syndrome. Glimepiride does not alter fertility. Impact in humans: limited data. |